EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Why Symptoms Linger in Quiescent Crohn’s Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways

Jonathan Golob, Krishna Rao, Jeffrey A Berinstein iD, Prashant Singh, William D Chey, Chung Owyang, Nobuhiko Kamada, Peter D R Higgins, Vincent Young, Shrinivas Bishu iD, Allen A Lee iD

Inflammatory Bowel Diseases · 03.03.2025 · 31 (3) · 763-776

DOI: 10.1093/ibd/izae238 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 14.11.2024. Verfasst von Jonathan Golob und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Crohn Disease, Sulfur, Metabolic Networks and Pathways, Gastrointestinal Microbiome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CCF, NIDDK NIH HHS, AHRQ HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Even in the absence of inflammation, persistent symptoms in patients with Crohn’s disease (CD) are prevalent and worsen quality of life. We previously demonstrated enrichment in sulfidogenic microbes in quiescent Crohn’s disease patients with (qCD + S) vs without persistent GI symptoms (qCD-S). Thus, we hypothesized that sulfur metabolic pathways would be enriched in stool while differentially abundant microbes would be associated with important sulfur metabolic pathways in qCD + S.

Methods

We performed a multicenter observational study nested within SPARC IBD. Quiescent inflammation was defined by fecal calprotectin level < 150 mcg/g. Persistent symptoms were defined by CD-PRO2. Active CD (aCD) and non-IBD diarrhea-predominant irritable bowel syndrome (IBS-D) were included as controls.

Results

Thirty-nine patients with qCD + S, 274 qCD-S, 21 aCD, and 40 IBS-D underwent paired shotgun metagenomic sequencing and untargeted metabolomic profiling. The fecal metabolome in qCD + S was significantly different relative to qCD-S and IBS-D but not aCD. Patients with qCD + S were enriched in sulfur-containing amino acid pathways, including cysteine and methionine, as well as serine, glycine, and threonine. Glutathione and nicotinate/nicotinamide pathways were also enriched in qCD + S relative to qCD-S, suggestive of mitochondrial dysfunction, a downstream target of H2S signaling. Multi-omic integration demonstrated that enriched microbes in qCD + S were associated with important sulfur metabolic pathways. Bacterial sulfur metabolic genes, including CTH, isfD, sarD, and asrC, were dysregulated in qCD + S. Finally, sulfur metabolites with and without sulfidogenic microbes showed good accuracy in predicting the presence of qCD + S.

Discussion

Microbial-derived sulfur pathways and downstream mitochondrial function are perturbed in qCD + S, which implicate H2S signaling in the pathogenesis of this condition. Future studies will determine whether targeting H2S pathways results in improved quality of life in qCD + S.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseSulfurMetabolic Networks and PathwaysGastrointestinal MicrobiomeHumansFemaleMaleAdultFecesMiddle AgedCase-Control StudiesIrritable Bowel SyndromeMetabolomicsQuality of LifeMetabolome

Stichwörter der Autor:innen

hydrogen sulfideinflammatory bowel diseasemetabolomicsmicrobiomequality of life

Substanzen

Sulfur

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.

ORCID-Profile: Jeffrey A Berinstein, Shrinivas Bishu, Allen A Lee

Förderung

  • CCF
  • NIDDK NIH HHS
  • AHRQ HHS
  • NIH HHS
  • Crohn’s & Colitis Foundation
  • National Institutes of Health

Zitieren

APA

Golob, J., Rao, K., Berinstein, J. A., Singh, P., Chey, W. D., Owyang, C., Kamada, N., Higgins, P. D. R., Young, V., Bishu, S., & Lee, A. A. (2025). Why Symptoms Linger in Quiescent Crohn’s Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways. Inflammatory Bowel Diseases, 31(3), 763-776. https://doi.org/10.1093/ibd/izae238

Vancouver

Golob J, Rao K, Berinstein JA, Singh P, Chey WD, Owyang C, et al. Why Symptoms Linger in Quiescent Crohn’s Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways. Inflammatory Bowel Diseases. 2025;31(3):763-776. doi:10.1093/ibd/izae238

BibTeX
@article{Golob2025,
  author = {Golob, Jonathan and Rao, Krishna and Berinstein, Jeffrey A and Singh, Prashant and Chey, William D and Owyang, Chung and Kamada, Nobuhiko and Higgins, Peter D R and Young, Vincent and Bishu, Shrinivas and Lee, Allen A},
  title = {Why Symptoms Linger in Quiescent Crohn’s Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {3},
  pages = {763--776},
  doi = {10.1093/ibd/izae238}
}
Kostenlos starten →